Amidst acute shortage of Remdesivir across the nation Jubilant Pharma has developed an oral substitute for the anti-viral drug. The pharma major stated it has completed safety trials in animals and healthy human volunteers in India using a novel oral formulation of Remdesivir. The proposed oral treatment is expected to be for five days.
Jubilant has now sought approval for additional studies for this oral formulation from the Drug Controller General of India (DCGI). Jubilant Pharma is one of the 7 companies in India who produce Remdesivir in partnership with Gilead.